drugset / Trial / NCT06082596
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the pharmacokinetic data and preliminary efficacy of BEBT-908 for injection, and to explore the relationship between the safety and efficacy of BEBT-908 for injection and related biomarkers.
Timeline
- Start
- 2016-03-02
- Primary completion
- 2019-03-08
- Completion
- 2019-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEBT-908 | Unknown | 10 mg/m2 | Intravenous |
| Subject | BEBT-908 | Unknown | 15 mg/m2 | Intravenous |
| Subject | BEBT-908 | Unknown | 22.5 mg/m2 | Intravenous |
| Subject | BEBT-908 | Unknown | 33.75 mg/m2 | Intravenous |
| Subject | BEBT-908 | Unknown | 45 mg/m2 | Intravenous |